✨ Free AI Report
Financière de Tubize SA: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Financière de Tubize SA
Company Research

Financière de Tubize SA: Business Overview, Financials & Competitive Analysis

Financière de Tubize SA scores 6/10 on the AskCyborg Cyborg Score (Solid). Dividend-paying holding company offering indirect leverage to UCB's immunology and CNS pipeline growth with modest volatility. The company provides stable exposure to a leading biopharmaceutical company with strong therapeutic focus areas. However, as a pure holding company with no independent operations, returns are entirely dependent on UCB's performance.

What is Financière de Tubize SA's industry? Financière de Tubize SA (financiere-tubize.be) operates in Investment Holdings / Biopharmaceutical (via UCB subsidiary). AskCyborg classifies Financière de Tubize SA under Investment Holdings / Biopharmaceutical (via UCB subsidiary) in its company registry.

Financière de Tubize is a Belgian holding company established in 1928 that serves as a pure-play investment vehicle. The company's sole significant asset is a 36.27% stake in UCB, a major biopharmaceutical company foc...

6/ 10Solid

Cyborg Score thesis

Dividend-paying holding company offering indirect leverage to UCB's immunology and CNS pipeline growth with modest...

Read the full analyst-debate transcript →
Industry Investment Holdings / Biopharmaceutical (via UCB subsidiary)
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Financière de Tubize SA Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Financière de Tubize SA

AskCyborg analysts argue the bull and bear cases for Financière de Tubize SA across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Financière de Tubize SA OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Financière de Tubize SA Overview

Pro stress-test →

Financière de Tubize is a Belgian holding company established in 1928 that serves as a pure-play investment vehicle. The company's sole significant asset is a 36.27% stake in UCB, a major biopharmaceutical company focused on discovering and developing treatments for immune system and central nervous system disorders.

Strategic Profile

Pro stress-test →

As a mono holding company, Financière de Tubize provides direct exposure to UCB's biopharmaceutical pipeline and global operations spanning multiple continents. The company benefits from UCB's specialization in high-value therapeutic areas including immunology and CNS treatment development, with R&D facilities across Belgium, Germany, Japan, the UK, and the US.

Competitive Landscape

Pro stress-test →

As a holding company, Financière de Tubize competes in the passive investment vehicle space rather than operating in pharmaceutical markets directly. Its competitive positioning depends entirely on UCB's standing among biopharmaceutical peers focused on immunology and CNS therapeutics, competing with companies like Roche, Novartis, and other CNS/immunology specialists.

Industry Context

Financière de Tubize SA operates in Investment Holdings / Biopharmaceutical (via UCB subsidiary).

Key facts

Founded: 1928 · Headquarters: Brussels, Belgium · Market cap: $11.7B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Financière de Tubize SA.

  • Pure-play holding company structure: 100% of investment value derives from 36.27% stake in UCB SA, creating direct correlation with subsidiary performance
  • Outperformer versus sector: Stock returned positive gains while Belgian pharma industry declined 19.9% year-over-year, demonstrating relative strength
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Stock trading at €146.00 with market cap of €6.5-11.7 billion across sources
  • Past 12 monthsStock appreciated 37.27% with stable weekly volatility of 6%, outperforming broader Belgian market by margin
Get alerted when Financière de Tubize SA has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RocheDiversified pharmaceutical and diagnostics company with strong CNS and immunology portfolios→NovartisGlobal biopharmaceutical leader with CNS and immunology therapeutic focus→JanssenMajor pharmaceutical company with immunology and neurology drug portfolio→

Compare Financière de Tubize SA with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Financière de Tubize SA operates in Investment Holdings / Biopharmaceutical (via UCB subsidiary). See how the rest of the sector scores on the Cyborg framework.

Browse Investment Holdings / Biopharmaceutical (via UCB subsidiary) research →
NEW · MCP server

Ask your AI assistant about Financière de Tubize SA

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Financière de Tubize SA and its top competitor on Cyborg Score”
“What did Financière de Tubize SA do this quarter?”
“Is Financière de Tubize SA a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Financière de Tubize SA do?+
Financière de Tubize is a Belgian holding company established in 1928 that serves as a pure-play investment vehicle. The company's sole significant asset is a 36.27% stake in UCB, a major biopharmaceutical company foc...
What is Financière de Tubize SA's Cyborg Score?+
Financière de Tubize SA has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Financière de Tubize SA's main competitors?+
Named competitors include Roche, Novartis, Janssen. The full competitive landscape is in the AskCyborg report.
How can I get the full Financière de Tubize SA research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Financière de Tubize SA research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Financière de Tubize SA over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Investment Holdings research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Bure Equity AB8F. Hoffmann-La Roche AG7Novartis AG